Loading...
•
Dec 31, 2019
CryoPort Q4 2019 Earnings Report
Cryoport announced record revenue for fiscal year 2019.
Key Takeaways
Cryoport reported a 73% increase in revenue for fiscal year 2019, driven by commercial agreements supporting Gilead’s YESCARTA® and Novartis’ KYMRIAH®. The company is expanding its infrastructure and expects continued growth in the regenerative medicine market.
Cryoport reported revenue of $33.9 million for fiscal year 2019, a 73% increase year over year.
Revenue from commercial therapies increased 295% over the prior year to $8.3 million.
Cryoport supports 436 clinical trials in the Regenerative Medicine market.
A record total of five Cryoport supported Marketing Authorization Applications (MAA’s) or Biologics Licensing Applications (BLA’s) were filed during the fourth quarter of 2019.
Forward Guidance
Cryoport anticipates continued expansion of the Regenerative Medicine market and expects to start generating revenue from the commercial launch of bluebird bio’s ZYNTEGLO™ in the first quarter of 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...